Analyst: J&J can endure hip lawsuits; CardioKinetix rides into Asia with heart implant;

@FierceMedDev: Sign up to receive our new publication FierceDiagnostics in your inbox each Wednesday. Sign up here | Follow @FierceMedDev

@DamianFierce: St. Jude won a CE mark for its next-gen renal denervation device. News | Follow @DamianFierce

@MarkHFierce: There's a new brain cancer MRI Dx approach, and Harvard Medical School is partially behind it. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce: Chip lined with human cells tests cancer drug delivery with minimal cost. FierceDrugDelivery article | Follow @MichaelGFierce

> Even though Johnson & Johnson ($JNJ) may pay $3 billion to settle lawsuits over recalled metal hip implants, the action shouldn't hurt the company, one investment observer says, predicting the company's medical devices and diagnostics arms are poised for long-term growth. Item

> CardioKinetix, a 2012 Fierce 15 winner, made its official entry into Asia, implanting its Parachute device into four Malaysian patients. News

> California's Avinger picked up a CE mark for its Pantheris device, which combines intravascular imaging with plaque-removal technology. Release

> PerkinElmer has won a CE mark for its EnLite Neonatal TREC, a test the company said is the first commercially available screening for severe combined immunodeficiency. More

> LeMaitre Vascular ($LMAT) in Burlington, MA, snatched up tiny Bay State rival InaVein for $2.5 million, gaining access to that company's less-invasive technique to remove varicose veins. Story

> A Wayne State University researcher believes that the use of transoral robotic surgery, traditionally to treat throat tumors, would give sleep apnea patients another treatment option. Item

Biotech News

@FierceBiotech: Popular yesterday: Gilead's sofosbuvir cures some of the toughest hepatitis C cases. Article | Follow @FierceBiotech

@JohnCFierce: Strange story: Low-profile Epirus lays claim to a PhIII success for Remicade biosimilar--backed by TPG, 5AM. News | Follow @JohnCFierce

@RyanMFierce: GoogleVentures bets on oral biologics from startup Rani Therapeutics. Report | Follow @RyanMFierce

@EmilyMFierce: Worm genome reveals possible drug targets. Item from FierceBiotech Research | Follow @EmilyMFierce

> Human 'mini brains' grown in lab could aid drug discovery. Article

> J&J hands over $75M payout as FDA countdown begins for ibrutinib. More

Pharma News

@FiercePharma: Trending on our website: Top 20 orphan drugs by 2018. Special Report | Follow @FiercePharma

@CarlyHFierce: China's Simcere going private thanks to $495M buyout by chairman. ICYMI yesterday | Follow @CarlyHFierce

> Novartis discount fails to persuade NICE on Afinitor in breast cancer. Article

> Bayer's Eylea challenges Novartis eye drug for share of new market. Report

Vaccines News

> Novartis begins shipping flu vaccines ahead of crucial season. Article

> Analysis finds most vaccines safe during breastfeeding. Report

> International Vaccine Institute inks Indian alliances. Item

> Herd immunity from GSK, Merck vaccines cutting hospitalizations. Story

> Low vaccination rate at megachurch linked to measles outbreak. Report

Pharma Manufacturing News

@EricPFierce: India's GRAF building nutraceutical plant. It sees the category as source of future revenue growth. Article | Follow @EricPFierce

> Injectable drugs to drive CMO growth. Story

> Fast-growing ICIG adds peptide manufacturer. Article

> Novartis OTC unit has another foul-up. Report

> DOJ files suit against plant with persistent issues. More